Piper Jaffray Maintains Neutral on Ionis Pharmaceuticals, Lowers Price Target to $70

Piper Jaffray maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutral and lowers the price target from $75 to $70.

Benzinga · 11/07/2019 12:07

Piper Jaffray maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutral and lowers the price target from $75 to $70.